Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
- PMID: 17704413
- DOI: 10.1200/JCO.2006.09.7451
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
Abstract
PURPOSEl: Childhood cancer survivors treated with anthracyclines and cardiac radiation are at risk for late-onset cardiotoxicity. The purpose of this study was to delineate the relationship between clinical factors and abnormalities of noninvasive cardiac testing (NICT).
Patients and methods: Participants were recruited from a long-term follow-up clinic. Study measures comprised physical examination, laboratory evaluation, echocardiogram, and ECG. Mean fractional shortening (FS) and afterload were compared for survivors who did (at risk [AR]) and did not (no risk [NR]) receive potentially cardiotoxic modalities, and with values expected for comparable age- and sex-matched controls.
Results: The 278 study participants (mean age, 18.1 years; median age, 16.8 years; range, 7.5 to 39.7 years) included 223 survivors AR for cardiotoxicity after treatment with anthracyclines (median dose +/- standard deviation [SD], 202 +/- 109 mg/m(2)) and/or cardiac radiation. Mean FS (+/- SD) was lower for AR (0.33 +/- 0.06) compared with NR survivors (0.36 +/- 0.05; P = .004) and normative controls (0.36 +/- 0.04; P < .001). Mean afterload (+/- SD) was higher for AR (58 +/- 21 g/cm(2)) compared with NR survivors (46 +/- 15 g/cm(2); P < .001) and normative controls (48 +/- 13 g/cm(2); P < .001). The distribution of FS and afterload among NR survivors did not differ from that of controls. After adjustment for age group at diagnosis and time since completion of therapy, anthracycline dose predicted decline in distribution of FS (P < .001) and increase in distribution of afterload (P < .001). Treatment with anthracycline doses >or= 100 mg/m(2) increased the risk of abnormal NICT; survivors who received >or= 270 mg/m(2) had a 4.5-fold excess risk of abnormal NICT (95% CI, 2.1 to 9.6) compared with controls.
Conclusion: Childhood cancer survivors treated with anthracycline doses >or= 270 mg/m(2) are at greatest risk for abnormalities of FS and afterload.
Similar articles
-
Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.Pediatr Blood Cancer. 2010 Apr;54(4):579-84. doi: 10.1002/pbc.22371. Pediatr Blood Cancer. 2010. PMID: 20014238
-
Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.Echocardiography. 2018 Feb;35(2):234-240. doi: 10.1111/echo.13743. Epub 2017 Nov 6. Echocardiography. 2018. PMID: 29106752
-
Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.Pediatr Blood Cancer. 2009 May;52(5):631-6. doi: 10.1002/pbc.21913. Pediatr Blood Cancer. 2009. PMID: 19127569
-
Cardiac complications in childhood cancer survivors treated with anthracyclines.Cardiol Young. 2015 Aug;25 Suppl 2:107-16. doi: 10.1017/S1047951115000906. Cardiol Young. 2015. PMID: 26377717 Review.
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
Cited by
-
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.Int J Cancer. 2023 Apr 15;152(8):1659-1667. doi: 10.1002/ijc.34326. Epub 2022 Oct 31. Int J Cancer. 2023. PMID: 36250317 Free PMC article. Clinical Trial.
-
Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79. doi: 10.1093/jnci/djn310. Epub 2008 Sep 23. J Natl Cancer Inst. 2008. PMID: 18812549 Free PMC article.
-
Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy.Cardiooncology. 2020 May 21;6:5. doi: 10.1186/s40959-020-00060-0. eCollection 2020. Cardiooncology. 2020. PMID: 32477593 Free PMC article.
-
Anthracycline cardiotoxicity: from bench to bedside.J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401. J Clin Oncol. 2008. PMID: 18669466 Free PMC article.
-
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.BMJ. 2009 Dec 8;339:b4606. doi: 10.1136/bmj.b4606. BMJ. 2009. PMID: 19996459 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials